TVRD - Cara Therapeutics, Inc.

3.1
0.090   2.903%

Share volume: 22,199
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$3.01
0.09
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 8%
Dept financing 5%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.73%
1 Month
-5.78%
3 Months
-28.57%
6 Months
-36.34%
1 Year
-83.55%
2 Year
342.86%
Key data
Stock price
$3.10
P/E Ratio 
0.00
DAY RANGE
$2.94 - $3.20
EPS 
-$4.98
52 WEEK RANGE
$2.75 - $43.65
52 WEEK CHANGE
-$85.25
MARKET CAP 
365.439 M
YIELD 
N/A
SHARES OUTSTANDING 
9.381 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
12-31-2024
NEXT EARNINGS DATE
04-29-2025
BETA 
-0.01
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$42,780
AVERAGE 30 VOLUME 
$52,757
Company detail
CEO: Christopher Posner
Region: US
Website: caratherapeutics.com
Employees: 80
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)

Recent news